Stereotactic Fractionated Radiotherapy in the Treatment of Juxtapapillary Choroidal Melanoma: The McGill University Experience
| Autor: | Jean Deschênes, Ahmed Shaban, Christine Corriveau, Alan Dal Pra, Kitty Shun, Rolina Al-Wassia, Chaim Edelstein, François DeBlois, Russel Ruo, Horacio Patrocinio, Fabio Cury, George Shenouda |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_treatment Ocular Melanoma Vision Disorders Radiosurgery Cataract Disease-Free Survival Eye Enucleation Retina medicine Humans Radiology Nuclear Medicine and imaging Melanoma Aged Retrospective Studies Aged 80 and over Radiation business.industry Choroid Neoplasms Quebec Dose fractionation Retrospective cohort study Middle Aged medicine.disease Tumor Burden medicine.anatomical_structure Oncology Dry Eye Syndromes Female Dose Fractionation Radiation Nuclear medicine business Complication Optic disc Retinopathy |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 81:e455-e462 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2011.05.012 |
| Popis: | To report our experience with linear accelerator-based stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma.We performed a retrospective review of 50 consecutive patients diagnosed with juxtapapillary choroidal melanoma and treated with linear accelerator-based stereotactic fractionated radiotherapy between April 2003 and December 2009. Patients with small to medium sized lesions (Collaborative Ocular Melanoma Study classification) located within 2 mm of the optic disc were included. The prescribed radiation dose was 60 Gy in 10 fractions. The primary endpoints included local control, enucleation-free survival, and complication rates.The median follow-up was 29 months (range, 1-77 months). There were 31 males and 29 females, with a median age of 69 years (range, 30-92 years). Eighty-four percent of the patients had medium sized lesions, and 16% of patients had small sized lesions. There were four cases of local progression (8%) and three enucleations (6%). Actuarial local control rates at 2 and 5 years were 93% and 86%, respectively. Actuarial enucleation-free survival rates at 2 and 5 years were 94% and 84%, respectively. Actuarial complication rates at 2 and 5 years were 33% and 88%, respectively, for radiation-induced retinopathy; 9.3% and 46.9%, respectively, for dry eye; 12% and 53%, respectively, for cataract; 30% and 90%, respectively, for visual loss [Snellen acuity (decimal equivalent),0.1]; 11% and 54%, respectively, for optic neuropathy; and 18% and 38%, respectively, for neovascular glaucoma.Linear accelerator-based stereotactic fractionated radiotherapy using 60 Gy in 10 fractions is safe and has an acceptable toxicity profile. It has been shown to be an effective noninvasive treatment for juxtapapillary choroidal melanomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|